Expressing support for the designation of July 15, 2026, as "Glioblastoma Awareness Day".
- Bill Number
- H.Res. 1270
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-05-07: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-07-07T20:20:38Z
AI-Generated Summary
Purpose
This House Resolution (H. Res. 1270) expresses the U.S. House of Representatives' support for designating July 15, 2026, as "Glioblastoma Awareness Day". Glioblastoma is the most common and aggressive type of malignant brain tumor. The resolution aims to raise public awareness about the disease, its challenges, and the need for better research and treatments.
Key Provisions
The resolution includes a detailed preamble highlighting facts about glioblastoma, such as:
- Over 13,000 estimated U.S. diagnoses in 2025 and 10,000 deaths annually.
- 5-year survival rate of only 7.1% and median survival of 9 months.
- High out-of-pocket medical costs for patients.
- Limited treatments: only 5 drugs and 1 device approved by the FDA since the 1920s.
- Recent changes in diagnostic criteria emphasizing molecular biomarker testing (tests identifying specific genetic markers in tumors).
- Establishment of the National Cancer Institute's Glioblastoma Therapeutics Network (GTN) in 2020 to speed up therapy development.
The core resolution states that the House:
- Supports the "Glioblastoma Awareness Day" designation.
- Encourages public awareness of patient needs and research opportunities.
- Honors those who have died or are living with the disease.
- Supports better treatments to improve survival and quality of life.
- Recognizes the role of molecular biomarker testing.
- Supports patients, families, friends, and caregivers.
- Urges collaboration among government, private, and nonprofit groups on research.
- Encourages ongoing investments in research, including through GTN.
Significant Changes to Existing Law
- None. This is a non-binding resolution that expresses opinion and encouragement but does not create, amend, or repeal any laws.
Potential Impacts
- Citizens: Increases public awareness of glioblastoma, potentially leading to more support for patients, caregivers, and fundraising for research.
- Government agencies: Signals congressional support for entities like the National Cancer Institute (NCI) and FDA, which may encourage future funding or priorities for brain tumor research, but imposes no mandates.
- No direct impacts on international relations.
- Overall, symbolic effects could indirectly boost research funding or clinical trials through heightened visibility.
Main Stakeholders Affected
- Patients and families: Honored and supported through awareness and calls for better treatments.
- Caregivers and survivors: Recognized for their role in research and advocacy.
- Medical and research community: Benefits from urged collaborations and investments (e.g., NCI's GTN, FDA approvals).
- Nonprofits and private organizations: Encouraged to partner on research.
- Congress and federal agencies: Positions them to prioritize glioblastoma in budgets or policies.
Notable Legal, Constitutional, or Political Implications
- Legal/Constitutional: None significant; resolutions like this are routine congressional tools for awareness and have no enforceable effect, respecting separation of powers.
- Political: Bipartisan (introduced by members from both parties); serves as a signal for potential future legislation or appropriations on cancer research, without controversy. Introduced May 7, 2026, and referred to the House Committee on Energy and Commerce.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Williams, Roger [R-TX-25]
Cosponsors (26)
Rep. Mast, Brian J. [R-FL-21], Rep. Auchincloss, Jake [D-MA-4], Rep. Schakowsky, Janice D. [D-IL-9], Rep. Tonko, Paul [D-NY-20], Rep. McCaul, Michael T. [R-TX-10], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Simpson, Michael K. [R-ID-2], Rep. Lawler, Michael [R-NY-17], Rep. Bacon, Don [R-NE-2], Rep. Salazar, Maria Elvira [R-FL-27], Rep. Quigley, Mike [D-IL-5], Rep. Carbajal, Salud O. [D-CA-24], Rep. Raskin, Jamie [D-MD-8], Rep. Lofgren, Zoe [D-CA-18], Rep. Bonamici, Suzanne [D-OR-1], Rep. McGovern, James P. [D-MA-2], Rep. Dingell, Debbie [D-MI-6], Rep. Davis, Donald G. [D-NC-1], Rep. Matsui, Doris O. [D-CA-7], Rep. Trahan, Lori [D-MA-3], Rep. Pappas, Chris [D-NH-1], Rep. Riley, Josh [D-NY-19], Rep. Hill, J. French [R-AR-2], Rep. Gottheimer, Josh [D-NJ-5], Rep. Soto, Darren [D-FL-9], Rep. Jackson, Jonathan L. [D-IL-1]
Recent Actions
- 2026-05-07: Referred to the House Committee on Energy and Commerce.
- 2026-05-07: Submitted in House
Bill Versions
- Expressing support for the designation of July 15, 2026, as "Glioblastoma Awareness Day". — issued 2026-05-07 — PDF (4 pages)